Seroprevalence of hepatitis B in two period birth cohorts of Bolivian children: effect of universal vaccination

Masuet-Aumatell, Cristina; Ramon-Torrell, Josep Maria; Casanova-Rituerto, Aurora; Banqué-Navarro, Marta; Dávalos-Gamboa, María del Rosario; Rodriguez, Sandra

doi:10.1093/trstmh/trt057

Cited by 3 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an study in Egypt It has also been reported that children with diabetics may not have effective concentrations of anti-HBs antibody after the primary vaccination (27). Moreover, there is a report of low long-term humoral immunity against HBV infection in vaccinated people in Bolivia (28). Patients with HIV infection may also lose their HBV vaccination response rapidly after completing the vaccination, so they need to be evaluated 6-12 months after finishing the primary vaccination series (29).…”

Section: The Present Situation Several Years After Starting the Sumentioning

confidence: 99%

Hepatitis B Vaccination: Needs a Revision

Rezaee‐Zavareh

Einollahi

2014

Hepat Mon

View full text Add to dashboard Cite

Section: The Present Situation Several Years After Starting the Sumentioning

confidence: 99%

Hepatitis B Vaccination: Needs a Revision

Rezaee‐Zavareh

Einollahi

2014

Hepat Mon

View full text Add to dashboard Cite

“…In Bolivia, another country with low endemicity prior to introduction of universal vaccination among children aged <1 year, a serological study with limited sample size (424 individuals) identified a persistent low prevalence of HBV infection after a decade of universal vaccination among children ages 5–16 years [35]. Quebec and British Columbia, like other provinces of Canada, initially opted for school-based pre-adolescent or adolescent HB immunization programs instead of routine infant vaccination.…”

Section: Resultsmentioning

confidence: 99%

Progress in vaccination towards hepatitis B control and elimination in the Region of the Americas

et al. 2017

View full text Add to dashboard Cite

BackgroundOver recent decades, the Region of the Americas has made significant progress towards hepatitis B elimination. We summarize the countries/territories’ efforts in introducing and implementing hepatitis B (HB) vaccination and in evaluating its impact on HB virus seroprevalence.MethodsWe collected information about HB vaccination schedules, coverage estimates, and year of vaccine introduction from countries/territories reporting to the Pan American Health Organization/World Health Organization (PAHO/WHO) through the WHO/UNICEF Joint Reporting Form on Immunization. We obtained additional information regarding countries/territories vaccination recommendations and strategies through communications with Expanded Program on Immunization (EPI) managers and national immunization survey reports. We identified vaccine impact studies conducted and published in the Americas.ResultsAs of October 2016, all 51 countries/territories have included infant HB vaccination in their official immunization schedule. Twenty countries, whose populations represent over 90% of the Region’s births, have included nationwide newborn HB vaccination. We estimated at 89% and 75%, the regional three-dose series and the birth dose HB vaccination coverage, respectively, for 2015. The impact evaluations of infant HB immunization programs in the Region have shown substantial reductions in HB surface antigen (HBsAg) seroprevalence.ConclusionThe achievements of vaccination programs in the Americas suggest that the elimination of perinatal and early childhood HB transmission could be feasible in the short-term. Moreover, the data gathered indicate that the Region may have already achieved the 2020 WHO goal for HB control.

show abstract

Hepatitis B Virus Infection in the General Population of Iran: An Updated Systematic Review and Meta-Analysis

et al. 2016

View full text Add to dashboard Cite

ContextThe hepatitis B virus (HBV) is a major global public health problem, affecting more than 2 billion people worldwide. Accurate and updated data on HBV prevalence is important for further planning to control the infection. The aim of this study was to update the prevalence estimate of HBV infection in the general population of Iran.Evidence AcquisitionA systematic review was done for data on the prevalence of HBV infection in the general Iranian population published between Jan. 1, 1990, and Jan. 1, 2016, in both international and national databases, including PubMed, Scopus, Web of Science, Scientific Information Database, IranMedex, and Magiran. All papers with clearly described time and location of the study, proper sampling strategies, and proper analysis methods were included in the present study. Data were extracted by two independent reviewers. Prevalence of HBV infection with a 95% confidence interval (CI) was calculated using Stata software, version 13.ResultsThe polled estimated prevalence of HBV infection in the general population of Iran was 2.2 % (95% CI: 1.9% - 2.6%). The highest prevalence of HBV infection (8.9%, 95% CI: 7.6% - 10.2%) was reported from Golestan province, and the lowest prevalence (0.7%, 95% CI: 0.4% - 1.1%) was seen in Kermanshah province. The prevalence of HBV infection was estimated at 3% (95% CI: 2.2% - 3.8%) for Iranian males and 1.7% (95% CI: 1.2% - 2.3%) for Iranian females. The prevalence of HBV infection in the general population of Iran was 2.9% (95% CI: 2.5% - 3.4%) before 2010 and 1.3% (95% CI: 0.9% - 1.7%) after 2010.ConclusionsIn total, Iran was classified within the low–intermediate HBV prevalence areas (2% - 4%), while according to recent data (after 2010), Iran was classified within the low HBV prevalence areas (< 2%), indicating that preventive measures conducted in Iran have been effective.

show abstract

Seroprevalence of hepatitis B in two period birth cohorts of Bolivian children: effect of universal vaccination

Abstract: This study identified a persistent low seroprevalence of hepatitis B infection in spite of a decade of universal immunization, and low long-term humoral immunity against HBV infection in vaccinated children in Cochabamba.

Cited by 3 publications

References 21 publications

Hepatitis B Vaccination: Needs a Revision

Hepatitis B Vaccination: Needs a Revision

Progress in vaccination towards hepatitis B control and elimination in the Region of the Americas

Hepatitis B Virus Infection in the General Population of Iran: An Updated Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About